Search results for "Gout"


 
Results 1 - 10 of about 10 for "Gout".

Urate-lowering therapy associated with benefit in patients with gout and CKD

The five-year risk of severe or end-stage chronic kidney disease (CKD) was lower in patients with CKD and gout who achieved a target serum urate level of less than 6 mg/dL compared to those who did not, data from the United Kingdom show.
https://immattersacp.org/weekly/archives/2024/12/03/4.htm
3 Dec 2024

Serum urate level may predict flare risk in patients with gout

Approximately 95% of acute gout episodes requiring treatment occurred in patients who had a serum urate level of at least 6 mg/dL at baseline while 98% occurred in those with a baseline level of at least 5 mg/dL, according to a study using UK Biobank data on 1,773 episodes over a mean follow-up of 8.3 years.
https://immattersacp.org/weekly/archives/2024/02/13/1.htm
13 Feb 2024

Allopurinol not associated with increased mortality in patients with CKD, gout

The findings of a database analysis from the United Kingdom provide reassurance that a treat-to-target strategy has no apparent harmful effect on mortality in patients with gout and chronic kidney disease (CKD).
https://immattersacp.org/weekly/archives/2022/01/25/2.htm
25 Jan 2022

Guideline recommends allopurinol as first-line therapy for gout

The American College of Rheumatology noted that the drug is the preferred choice for urate-lowering therapy in all patients, including those with moderate to severe chronic kidney disease.
https://immattersacp.org/weekly/archives/2020/05/19/4.htm
19 May 2020

Studies analyze causes of hyperuricemia, kidney effects of gout treatment with allopurinol

Genetics contribute more than diet to hyperuricemia in healthy people, and 300 mg of allopurinol per day was associated with lower risk of chronic kidney disease in people with gout, recent research found.
https://immattersacp.org/weekly/archives/2018/10/16/1.htm
16 Oct 2018

Cardiovascular safety of febuxostat and allopurinol compared in patients with gout and CVD

In a modified intention-to-treat analysis, the primary end point of first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization for unstable angina occurred in 10.8% of patients taking febuxostat and in 10.4% of patients taking allopurinol (hazard ratio, 1.03).
https://immattersacp.org/weekly/archives/2018/03/20/4.htm
20 Mar 2018

Clinical practice guideline for acute gout recommends corticosteroids, NSAIDs, low-dose colchicine

For diagnosis, a separate guideline recommended that physicians use synovial fluid analysis when clinical judgment indicates that diagnostic testing is necessary in patients with possible gout.
https://immattersacp.org/weekly/archives/2016/11/01/1.htm
1 Nov 2016

Corticosteroids may be viable first-line alternative to NSAIDs for acute gout

The study provides evidence that oral corticosteroids are as effective at treating pain and as acceptable to patients as non-steroidal anti-inflammatory drugs, and that they should be considered as a first-line alternative in the treatment of patients with acute gout.
https://immattersacp.org/weekly/archives/2016/02/23/4.htm
23 Feb 2016

Nighttime gout attack risk may be twice as much as in daytime

The risk of acute gout attacks was more than twice as high during the night or early morning hours than the day, even among those who did not consume alcohol and had a low purine intake during the 24 hours prior to the attack, a study found.
https://immattersacp.org/weekly/archives/2014/12/16/5.htm
16 Dec 2014

Pegloticase effective in treatment refractory patients

The drug pegloticase successfully treated gout in patients who had been refractory to conventional treatment.
https://immattersacp.org/weekly/archives/2011/08/23/5.htm
23 Aug 2011

Prev   1   Next